Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Advanced Solid Tumors
NCT04503278Phase 1Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Sep 2020
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 4
01
Overview
Phase 1, open-label trial of BNT211 and cldn6 modrna-lpx in solid tumor (2 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-Emergent Adverse Events up to 25 months, Dose reduction and discontinuation of IMP due to TEAEs up to 25 months and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
BNT211cldn6 modrna-lpx
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04503278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503278.